Dr. David Horn Solomon, CEO of Pharnext discusses #PXT3003 which is currently focused on the treatment of Charcot Marie-Tooth (#CMT) disease Type 1A.
#Charcot-Marie-Tooth is a degenerative nerve disease that usually appears in adolescence or early adulthood. CMT affects the Peripheral Nervous System. It is a progressive nerve disease. Nerves weaken over time, causing progressive disability starting in the toes and fingers and working toward the center of the body.
You can visit Pharnext by clicking on this link: [ Ссылка ]
About:
Dr. Solomon is a leader in the life sciences industry with a 30+ year track record. Prior to joining Pharnext, David served as the CEO of Silence Therapeutics (NASDAQ:SLN), Akari Therapeutics (NASDAQ:AKRI), Bionor Pharma (OSLO:BIONOR), and Zealand Pharma (NASDAQ:ZEAL) guiding Zealand through approval of Adlixin for Type II Diabetes. He was Managing Partner at Sund Capital in Denmark and also headed healthcare investments at Carrot Capital Healthcare Ventures in New York City. A former Board member of TxCell (acquired by Sangamo Therapeutics), Onxeo, and Promosome, David is currently Chairman of the Board for Advicenne Pharma (PARIS: ADV) and Rexgenero in London. David was earlier a Professor of Pharmacology and Neurology at Columbia University’s College of Physicians and Surgeons in New York City.
